184 related articles for article (PubMed ID: 27334394)
1. Second medical use in Turkey.
Baklaci E; Altınay M
Pharm Pat Anal; 2016 Jul; 5(4):199-201. PubMed ID: 27334394
[TBL] [Abstract][Full Text] [Related]
2. Does European patent law unfairly discriminate against medical devices as compared with pharmaceuticals?
Sterckx S
Expert Opin Ther Pat; 2015; 25(8):845-8. PubMed ID: 25892308
[TBL] [Abstract][Full Text] [Related]
3. Debate on patentability of biotechnological studies in Turkey.
Memiş T
Rev Derecho Genoma Hum; 2007; (26):121-35. PubMed ID: 18201040
[TBL] [Abstract][Full Text] [Related]
4. The immoral gene: does it really exist?
Zimmer FJ; Sethmann S
Sci Eng Ethics; 2005 Jan; 11(1):97-104. PubMed ID: 15727005
[TBL] [Abstract][Full Text] [Related]
5. [The generic Research and Development possibilities after Hungary accessed th European Patent Convention].
Kelen A; Angyal N; Máthé Z; Bódis A; Hódi K
Acta Pharm Hung; 2003; 73(2):123-9. PubMed ID: 14702693
[TBL] [Abstract][Full Text] [Related]
6. Patent prosecution at the European Patent Office: what is new for life sciences applicants?
Lidén C; Setréus E
Expert Opin Ther Pat; 2011 Jun; 21(6):813-7. PubMed ID: 21457106
[TBL] [Abstract][Full Text] [Related]
7. [Dosing regimens in second medical use patents].
Suganuma CA
Cad Saude Publica; 2017 Sep; 33(9):e00096716. PubMed ID: 28977273
[TBL] [Abstract][Full Text] [Related]
8. No change in scope for extension of patent term for pharmaceutical substances under Australian law: an update.
Lyons M; Stark A
Pharm Pat Anal; 2017 Nov; 6(6):251-254. PubMed ID: 29022759
[No Abstract] [Full Text] [Related]
9. Second medical use claims and 'skinny' labels: clear guidance at last?
Duncan G; Willoughby R
Pharm Pat Anal; 2016 May; 5(3):137-9. PubMed ID: 27087358
[No Abstract] [Full Text] [Related]
10. Relationships between the academic community and the pharmaceutical industry: the legislative background and its effect on spending on medical research and development.
Matthews JH
Clin Invest Med; 1996 Dec; 19(6):470-8. PubMed ID: 8959357
[TBL] [Abstract][Full Text] [Related]
11. Patent law and pharmaceutical products. A comparative study of the legal aspects of medical-pharmaceutical inventions in patent law.
Schutjens MH
Pharm World Sci; 1994 Jun; 16(3):161-3. PubMed ID: 7920368
[No Abstract] [Full Text] [Related]
12. Patenting pharmaceuticals in China.
Han W; Luo J
Pharm Pat Anal; 2016 Jul; 5(4):249-59. PubMed ID: 27338759
[TBL] [Abstract][Full Text] [Related]
13. Enhanced scope for extension of patent term for pharmaceuticals under Australian law.
Lyons M; Stark A
Pharm Pat Anal; 2015; 4(5):351-5. PubMed ID: 26490425
[No Abstract] [Full Text] [Related]
14. Patents on diagnostic methods in Europe under the European Patent Convention (EPC).
Barba M
Annu Int Conf IEEE Eng Med Biol Soc; 2010; 2010():2979-81. PubMed ID: 21095714
[TBL] [Abstract][Full Text] [Related]
15. Patent protection in Europe of pharmaceuticals found to have a further medical indication.
Cockbain J
Pharm Pat Anal; 2012 Mar; 1(1):17-8. PubMed ID: 24236708
[No Abstract] [Full Text] [Related]
16. Pharmaceutical patent law: the Canadian perspective.
Aumand L; Norman J
Pharm Pat Anal; 2016 Jul; 5(4):271-9. PubMed ID: 27346187
[TBL] [Abstract][Full Text] [Related]
17. India: Court upholds patent law denying patents for slightly modified versions of existing drugs.
Swamy M
HIV AIDS Policy Law Rev; 2007 Dec; 12(2-3):50-1. PubMed ID: 18459215
[TBL] [Abstract][Full Text] [Related]
18. Patenting of genome research results.
Stolzenburg F; Weinzierl G; Jaenichen HR
Pharmacogenomics; 2003 Sep; 4(5):633-42. PubMed ID: 12943469
[TBL] [Abstract][Full Text] [Related]
19. Patent watch: extra exclusivity for new medical uses.
Harrison C
Nat Rev Drug Discov; 2012 Sep; 11(9):666. PubMed ID: 22935795
[No Abstract] [Full Text] [Related]
20. Patent protection: a need for value-based patents.
Mardikar HM; Deshpande NV; Ghadyalpatil NS; Mardikar M
Lancet; 2003 Feb; 361(9357):613. PubMed ID: 12598169
[No Abstract] [Full Text] [Related]
[Next] [New Search]
